Dr. Abato provides expert witness services in connection with Hatch-Waxman type ANDA and patent infringement litigation in the area of pharmaceutical technology. Dr Abato has been deposed twice, sat in and advised counsel on two other depositions, was involved with one pretrial preparation and has testified in a federal court.
Dr Abato has been involved in all aspects of drug research and development from formulation development, synthesis/purification, in-vitro, in-vivo (efficacy and pharmacokinetics), dosing routs, and the management of CROs to support pre-clinical testing.
His services as an expert witness have been retained a major Generic Pharmaceutical Company, where he was deposed and participated in pretrial preparation. Dr Abato has also served as an expert witness for a Nutraceutical Company were he gave testimony at trial regarding a patented formulation. Currently his services have been retained by an undisclosed generic pharmaceutical company involved in an ANDA dispute. Dr Abato also is presently consulting for an undisclosed pharmaceutical company where he oversee radio-labled syntheses of active pharmaceutical agents for pharmacokinetic studies.
A Ph. D. Medicinal Chemist with 20 years experience in the discovery and development of novel human therapeutics in the areas of anti-infective, anti-inflammatory and neurodegenerative diseases. He contributed to the development of Omadacycline, a new antibiotic, recently approved by the FDA.